FDA cancels adcomm on Biohaven drug; Catalent lays off staff
  1. Biotechnology

FDA cancels adcomm on Biohaven drug; Catalent lays off staff

Written by Posted on Less than 0 min read

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.

Member since

More from BioPharma Dive staff

Next
No Comments
Leave a comment Cancel
Comments to: FDA cancels adcomm on Biohaven drug; Catalent lays off staff

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.